BACKGROUND: Inflammation and hemostasis perturbation may be involved in vascular complications of HIV infection. We examined atherogenic biomarkers and subclinical atherosclerosis in HIV-infected adults before and after beginning highly active antiretroviral therapy (HAART). METHODS: In the Women's Interagency HIV Study, 127 HIV-infected women studied pre and post HAART were matched to HIV-uninfected controls. Six semiannual measurements of soluble CD14, tumor necrosis factor (TNF) alfa, soluble interleukin (IL) 2 receptor, IL-6, IL-10, monocyte chemoattractant protein 1, D-dimer, and fibrinogen were obtained. Carotid artery intima-media thickness was measured by B-mode ultrasound. RESULTS: Relative to HIV-uninfected controls, HAART-naive HIV-infected women had elevated levels of soluble CD14 (1945 vs 1662 ng/mL, Wilcoxon signed rank P < 0.0001), TNF-α (6.3 vs 3.4 pg/mL, P < 0.0001), soluble IL-2 receptor (1587 vs 949 pg/mL, P < 0.0001), IL-10 (3.3 vs 1.9 pg/mL, P < 0.0001), monocyte chemoattractant protein 1 (190 vs 163 pg/mL, P < 0.0001), and D-dimer (0.43 vs 0.31 μg/mL, P < 0.01). Elevated biomarker levels declined after HAART. Although most biomarkers normalized to HIV-uninfected levels, in women on effective HAART, TNF-α levels remained elevated compared with HIV-uninfected women (+0.8 pg/mL, P = 0.0002). Higher post-HAART levels of soluble IL-2 receptor (P = 0.02), IL-6 (P = 0.05), and D-dimer (P = 0.03) were associated with increased carotid artery intima-media thickness. CONCLUSIONS: Untreated HIV infection is associated with abnormal hemostasis (eg, D-dimer), proatherogenic (eg, TNF-α), and antiatherogenic (eg, IL-10) inflammatory markers. HAART reduces most inflammatory mediators to HIV-uninfected levels. Increased inflammation and hemostasis are associated with subclinical atherosclerosis in recently treated women. These findings have potential implications for long-term risk of cardiovascular disease in HIV-infected patients, even with effective therapy.
BACKGROUND: Inflammation and hemostasis perturbation may be involved in vascular complications of HIV infection. We examined atherogenic biomarkers and subclinical atherosclerosis in HIV-infected adults before and after beginning highly active antiretroviral therapy (HAART). METHODS: In the Women's Interagency HIV Study, 127 HIV-infected women studied pre and post HAART were matched to HIV-uninfected controls. Six semiannual measurements of soluble CD14, tumor necrosis factor (TNF) alfa, soluble interleukin (IL) 2 receptor, IL-6, IL-10, monocyte chemoattractant protein 1, D-dimer, and fibrinogen were obtained. Carotid artery intima-media thickness was measured by B-mode ultrasound. RESULTS: Relative to HIV-uninfected controls, HAART-naive HIV-infected women had elevated levels of soluble CD14 (1945 vs 1662 ng/mL, Wilcoxon signed rank P < 0.0001), TNF-α (6.3 vs 3.4 pg/mL, P < 0.0001), soluble IL-2 receptor (1587 vs 949 pg/mL, P < 0.0001), IL-10 (3.3 vs 1.9 pg/mL, P < 0.0001), monocyte chemoattractant protein 1 (190 vs 163 pg/mL, P < 0.0001), and D-dimer (0.43 vs 0.31 μg/mL, P < 0.01). Elevated biomarker levels declined after HAART. Although most biomarkers normalized to HIV-uninfected levels, in women on effective HAART, TNF-α levels remained elevated compared with HIV-uninfected women (+0.8 pg/mL, P = 0.0002). Higher post-HAART levels of soluble IL-2 receptor (P = 0.02), IL-6 (P = 0.05), and D-dimer (P = 0.03) were associated with increased carotid artery intima-media thickness. CONCLUSIONS: Untreated HIV infection is associated with abnormal hemostasis (eg, D-dimer), proatherogenic (eg, TNF-α), and antiatherogenic (eg, IL-10) inflammatory markers. HAART reduces most inflammatory mediators to HIV-uninfected levels. Increased inflammation and hemostasis are associated with subclinical atherosclerosis in recently treated women. These findings have potential implications for long-term risk of cardiovascular disease in HIV-infected patients, even with effective therapy.
Authors: Frank J Palella; Stephen J Gange; Lorie Benning; Lisa Jacobson; Robert C Kaplan; Alan L Landay; Russell P Tracy; Richard Elion Journal: AIDS Date: 2010-07-17 Impact factor: 4.177
Authors: Rebecca K Lodwick; Caroline A Sabin; Kholoud Porter; Bruno Ledergerber; Ard van Sighem; Alessandro Cozzi-Lepri; Pavel Khaykin; Amanda Mocroft; Lisa Jacobson; Stephane De Wit; Niels Obel; Antonella Castagna; Jan-Christian Wasmuth; John Gill; Marina B Klein; Stephen Gange; Melchor Riera; Cristina Mussini; Félix Gutiérrez; Giota Touloumi; Patrizia Carrieri; Jodie L Guest; Norbert H Brockmeyer; Andrew N Phillips Journal: Lancet Date: 2010-07-15 Impact factor: 79.321
Authors: Matteo Cesari; Brenda W J H Penninx; Anne B Newman; Stephen B Kritchevsky; Barbara J Nicklas; Kim Sutton-Tyrrell; Susan M Rubin; Jingzhong Ding; Eleanor M Simonsick; Tamara B Harris; Marco Pahor Journal: Circulation Date: 2003-10-20 Impact factor: 29.690
Authors: Leslie Cockerham; Rebecca Scherzer; Andrew Zolopa; David Rimland; Cora E Lewis; Peter Bacchetti; Carl Grunfeld; Michael Shlipak; Phyllis C Tien Journal: J Acquir Immune Defic Syndr Date: 2010-01 Impact factor: 3.731
Authors: Andrew T Yan; Raymond T Yan; Mary Cushman; Alban Redheuil; Russell P Tracy; Donna K Arnett; Boaz D Rosen; Robyn L McClelland; David A Bluemke; Joao A C Lima Journal: Eur Heart J Date: 2010-01-10 Impact factor: 29.983
Authors: Jason M Brenchley; David A Price; Timothy W Schacker; Tedi E Asher; Guido Silvestri; Srinivas Rao; Zachary Kazzaz; Ethan Bornstein; Olivier Lambotte; Daniel Altmann; Bruce R Blazar; Benigno Rodriguez; Leia Teixeira-Johnson; Alan Landay; Jeffrey N Martin; Frederick M Hecht; Louis J Picker; Michael M Lederman; Steven G Deeks; Daniel C Douek Journal: Nat Med Date: 2006-11-19 Impact factor: 53.440
Authors: Lewis H Kuller; Russell Tracy; Waldo Belloso; Stephane De Wit; Fraser Drummond; H Clifford Lane; Bruno Ledergerber; Jens Lundgren; Jacqueline Neuhaus; Daniel Nixon; Nicholas I Paton; James D Neaton Journal: PLoS Med Date: 2008-10-21 Impact factor: 11.069
Authors: Christina M Parrinello; Alan L Landay; Howard N Hodis; Stephen J Gange; Philip J Norris; Mary Young; Kathryn Anastos; Phyllis C Tien; Xiaonan Xue; Jason Lazar; Lorie Benning; Russell P Tracy; Robert C Kaplan Journal: AIDS Date: 2013-06-01 Impact factor: 4.177
Authors: Nikolas Itaru Wada; Lisa P Jacobson; Joseph B Margolick; Elizabeth Crabb Breen; Bernard Macatangay; Sudhir Penugonda; Otoniel Martínez-Maza; Jay H Bream Journal: AIDS Date: 2015-02-20 Impact factor: 4.177
Authors: Roksana Karim; Wendy J Mack; Naoko Kono; Phyllis C Tien; Kathryn Anastos; Jason Lazar; Mary Young; Seema Desai; Elizabeth T Golub; Robert C Kaplan; Howard N Hodis; Andrea Kovacs Journal: J Acquir Immune Defic Syndr Date: 2014-11-01 Impact factor: 3.731
Authors: Jessica L Montoya; Jennifer Iudicello; Hannah A Oppenheim; Pariya L Fazeli; Michael Potter; Qing Ma; Paul J Mills; Ronald J Ellis; Igor Grant; Scott L Letendre; David J Moore Journal: AIDS Date: 2017-03-27 Impact factor: 4.177
Authors: Matthew E Levy; Alan E Greenberg; Manya Magnus; Naji Younes; Amanda Castel Journal: AIDS Res Hum Retroviruses Date: 2018-11-27 Impact factor: 2.205
Authors: Iftach Shaked; David B Hanna; Christian Gleißner; Brenda Marsh; Jill Plants; Daniel Tracy; Kathryn Anastos; Mardge Cohen; Elizabeth T Golub; Roksana Karim; Jason Lazar; Vinayaka Prasad; Phyllis C Tien; Mary A Young; Alan L Landay; Robert C Kaplan; Klaus Ley Journal: Arterioscler Thromb Vasc Biol Date: 2014-03-20 Impact factor: 8.311